Compare Levi Strauss & Co. (LEVI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Novavax Inc — how do they compare? Levi Strauss & Co. trades at $23.97 (market cap $9.21B), while Novavax Inc trades at $7.9 (market cap $1.30B). The key difference: Levi Strauss & Co. is far larger — about 7.1× Novavax Inc's market cap, and Levi Strauss & Co. pays a 2.68% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| LEVI | NVAX | |
|---|---|---|
Market Cap | $9.21B | $1.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.99 | $11.19 |
52-Week Low | $17.92 | $6.22 |
Enterprise Value | $10.52B | $800.50M |
Dividend Yield | 2.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
